降脂领域的新星——PCSK9抑制剂  

A rising star in lipidology:PCSK9 inhibitor

作　　者：钱菊英 王箴 QIAN Juying WANG Zhen(Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, 200032, Chin)

机构地区：[1]复旦大学附属中山医院心内科上海市心血管病研究所,上海200032

出　　处：《临床心血管病杂志》2017年第9期821-824,共4页Journal of Clinical Cardiology

摘　　要：前蛋白转化酶枯草溶菌素9(PCSK9)单克隆抗体抑制剂通过减少低密度脂蛋白胆固醇受体(LDLR)的降解,从而显著降低血浆低密度脂蛋白胆固醇(LDL-C)水平,并可以进一步减少临床事件的发生、改善预后,同时也是安全的。临床上PCSK9抑制剂可以用于治疗家族性高胆固醇血症患者或临床动脉粥样硬化心血管疾病患者,在控制饮食和最大耐受他汀治疗下仍需进一步降低LDL-C的患者。但由于目前价格昂贵,成本效益比可能会限制其在临床的广泛应用。PCSK9 inhibitor,the f human monoclonal antibody,dramatically reduces LDL-C level by decreasing the degeneration of LDL receptor.Clinical trials has also shown that it reduces major adverse cardiovascular events and improves prognosis without safety problems.Clinical indications of PCSK9 inhibitor include patients with familial hypercholesterolemia and patients with atherosclerosis cardiovascular disease who need further lower LDL-C level and have already received optimal diet and maximum dosage of statins.However,high price of PCSK9 inhibitor makes it less cost-effective in most of the patients for either primary or secondary prevention by now.

关 键 词：PCSK9人单克隆抗体 PCSK9抑制剂 低密度脂蛋白胆固醇 

分 类 号：R543.5[医药卫生—心血管疾病]